



For Immediate Release

CyGenics Appoints New Directors

Key Points:

- New board directors appointed - Seow Bao Shuen and Peter Roberts
- Ian Brown has been appointed Chief Investments Officer, focusing on the Company's technology portfolio

5th February 2007 – Leading healthcare company CyGenics Ltd (ASX: CYN) today announced that it had appointed two new non-executive directors.

Seow Bao Shuen brings with her more than 10 years of management experience, in strategic formulation, business development, and the implementation of management policies. She was previously a director in listed Citiraya Industries Ltd, before forming a venture capital fund, BS Fund Management and property investments group, BS Capital. She is currently Managing Director of Cimelia Resource Recovery Pte Ltd, a globally recognised electronic waste recycling and precious metals refinery leader, and also sits on the board of Singapore Stock Exchange listed company, Enviro-Hub Holdings Ltd.

Peter Roberts has more than 35 years experience in business. Currently, he is the Managing Director of Jennmar Australia Pty Ltd, a privately owned manufacturing enterprise, and a non-executive director of IMD Group Ltd, a company listed on the Australian Stock Exchange. His previous experience includes 21 years with PricewaterhouseCoopers, Chartered Accountants, 12 years as a partner. He holds a Bachelor of Economics degree from Sydney University and is a Fellow of the Institute of Chartered Accountants.

The Company also announced that Ian Brown has been appointed the Chief Investments Officer, focusing on the management of the Company's technology portfolio, as well as investor and public relations. Ian will be supported by our CSO, Associate Professor Mark Kirkland and others key executives. Ian previously held the position of COO and executive director.

“As the Company strengthens its focus on its revenue generating tissue and cord blood banking business, the input of experienced senior executives such as Bao Shuen and Peter will be invaluable,” said Chris Fullerton, Chairman, CyGenics.



About CyGenics

CyGenics (ASX: CYN), is a healthcare company focussed on tissue and cord blood banking. CyGenics owns and operates the largest network of private cord blood banks in the Australasian region and has a portfolio of stem cell technology related investments. Its major subsidiary, CordLife, is a regional cord blood bank that operates a state-of-the-art AABB (formerly known as the American Association of Blood Banks) accredited facility in Singapore and a separate compliant facility in Hong Kong. CordLife's facility was the first private cord blood bank to be set up in Singapore, and among the first in Asia. It is the only AABB-accredited cord blood bank in this region. These banking facilities comprise full processing and cryogenic storage capabilities. For further information, please visit www.cygenics.com or www.cordlife.com.

About Cord Blood Stem Cells

Cord blood stem cells are most commonly used to treat several different types of blood cancers, such as acute leukemias, other blood disorders and various inherited disorders. Stem cells from cord blood are described as 'adult' to distinguish them from the stem cells derived from embryos. Research into the use of these cells has shown that adult stem cells can also be used to treat autoimmune diseases such as lupus, multiple sclerosis, Crohn's disease, and rheumatoid arthritis. Early clinical studies also suggest that they can help avert corneal degeneration and restore vision in cases of blindness, can help to restore proper cardiac function to heart attack sufferers and can improve movement in spinal cord injury patients. Stem cells from cord blood have a number of advantages over stem cells collected later in life, including a lower risk of rejection.

For more information, please contact:

Ian Brown, CIO
Ph: +61 (0)3 9642 5580
Mob: +61 (0)438 565 212
Email: ian.brown@cygenics.com

Steven Fang, CEO
Ph: +61 (0)3 9642 5580
Mob: +61 (0)400 933 243
Email: steven.fang@cygenics.com

Ronald Hee
Mob: +65 9061 9098
Email: ronald.hee@cygenics.com